Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases

Hepatology

Volumn 42, Issue 4, 2005, Pages 838-845

  Colletta, Cosimo ^a   Smirne, Carlo ^b   Fabris, Carlo ^c   Toniutto, Pierluigi ^c   Rapetti, Rachele ^b   Minisini, Rosalba ^b   Pirisi, Mario ^b  

^a Madonna del Popolo Hospital   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; ALGORITHM; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ARTIFICIAL INTELLIGENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE COURSE; ECHOGRAPHY; ELASTOGRAPHY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; MALE; MULTIVARIATE ANALYSIS; NON INVASIVE MEASUREMENT; NORMAL VALUE; OBSERVER VARIATION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; VIRUS CARRIER; VIRUS LOAD; WEIGHTED KAPPA ANALYSIS;

EID: 25844439419     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20814     Document Type: Article

References (28)

1. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. HEPATOLOGY 1997;26:133S-136S.
2. Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
3. Puoti C. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J Hepatol 2003;38:529-532.
4. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. HEPATOLOGY 1998;27:868-872.
5. Puoti C, Castellacci R, Montagnese F, Zaltron S, Stornaiuolo G, Bergami N, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002;37:117-123.
6. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000;133:665-675.
7. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
8. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Virol Hepatol 2002; 9:128-133.
9. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. HEPATOLOGY 2004;41:48-54.
10. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.
11. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography. Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
12. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: 696-699.
13. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996;24:289-293.
14. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
15. International drinking guidelines. Washington, DC: International Center for Alcohol Policies; 2003, December. Report No. 14. Available at: http:// www.icap.org/opencms/opencms/system/galleries/download/all_pdfs/ ICAP_Reports_English/report14.pdf. Accessed May 17, 2005.
16. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
17. Bonny C, Rayssiguier R, Ughetto S, Aubler-Cuvelier B, Baranger J, Blanchet G, et al. [Medical practices and expectations of general practitioners in relation to hepatitis C virus infection in the Auvergne region]. Gastroenterol Clin Biol 2003;27:1021-1025.
18. Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. HEPATOLOGY 1994;19:871-875.
19. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. HEPATOLOGY 1995;22:418-425.
20. Puoti C, Stati T, Magrini A. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver 1999;19:104-109.
21. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. HEPATOLOGY 1998;27:1717-1722.
22. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. HEPATOLOGY 1997;26(Suppl):2S-10S.
23. EASL International Consensus Conference on Hepatitis C. Paris, 26-28. February 1999. Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-961.
24. Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver. Can J Gastroenterol 2000; 14(Suppl B):5B-20B.
25. Van Thiel DH, Colantoni A, De Maria N. Treatment of HCV positive individuals with normal serum ALT levels. Hepatogastroenterology 1998; 45:321-324.
26. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003;38:511-517.
27. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732.
28. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-237.